These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 17450046)

  • 21. A double-blind, placebo-controlled trial of dexmethylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in children with attention-deficit/hyperactivity disorder.
    Wigal S; Swanson JM; Feifel D; Sangal RB; Elia J; Casat CD; Zeldis JB; Conners CK
    J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1406-14. PubMed ID: 15502600
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
    J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.
    Coghill D; Banaschewski T; Lecendreux M; Soutullo C; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Lyne A; Squires L
    Eur Neuropsychopharmacol; 2013 Oct; 23(10):1208-18. PubMed ID: 23332456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of methylphenidate on aggressive urban children with attention deficit hyperactivity disorder.
    Bukstein OG; Kolko DJ
    J Clin Child Psychol; 1998 Oct; 27(3):340-51. PubMed ID: 9789193
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder.
    Findling RL; Bukstein OG; Melmed RD; López FA; Sallee FR; Arnold LE; Pratt RD
    J Clin Psychiatry; 2008 Jan; 69(1):149-59. PubMed ID: 18312050
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Children with ADHD and symptoms of oppositional defiant disorder improved in behavior when treated with methylphenidate and adjuvant risperidone, though weight gain was also observed - Results from a randomized, double-blind, placebo-controlled clinical trial.
    Jahangard L; Akbarian S; Haghighi M; Ahmadpanah M; Keshavarzi A; Bajoghli H; Sadeghi Bahmani D; Holsboer-Trachsler E; Brand S
    Psychiatry Res; 2017 May; 251():182-191. PubMed ID: 28213188
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ginkgo biloba for attention-deficit/hyperactivity disorder in children and adolescents: a double blind, randomized controlled trial.
    Salehi B; Imani R; Mohammadi MR; Fallah J; Mohammadi M; Ghanizadeh A; Tasviechi AA; Vossoughi A; Rezazadeh SA; Akhondzadeh S
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb; 34(1):76-80. PubMed ID: 19815048
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Methylphenidate an effective treatment for ADHD?
    McDougle CJ
    J Autism Dev Disord; 2004 Oct; 34(5):593-4. PubMed ID: 15628613
    [No Abstract]   [Full Text] [Related]  

  • 30. Standardized Observation Analogue Procedure in the Treatment of Severe Childhood Aggression Study.
    Grondhuis SN; Farmer CA; Arnold LE; Gadow KD; Findling RL; Molina BSG; Kolko DJ; Buchan-Page KA; Rice RR; Butter EM; Aman MG
    J Child Adolesc Psychopharmacol; 2020 Feb; 30(1):48-54. PubMed ID: 31730370
    [No Abstract]   [Full Text] [Related]  

  • 31. Risperidone-to-methylphenidate switch reaction in children: three cases.
    Sabuncuoglu O
    J Psychopharmacol; 2007 Mar; 21(2):216-9. PubMed ID: 17329303
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quetiapine addition in methylphenidate treatment-resistant adolescents with comorbid ADHD, conduct/oppositional-defiant disorder, and aggression: a prospective, open-label study.
    Kronenberger WG; Giauque AL; Lafata DE; Bohnstedt BN; Maxey LE; Dunn DW
    J Child Adolesc Psychopharmacol; 2007 Jun; 17(3):334-47. PubMed ID: 17630867
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study.
    Wigal SB; Nordbrock E; Adjei AL; Childress A; Kupper RJ; Greenhill L
    CNS Drugs; 2015 Apr; 29(4):331-40. PubMed ID: 25877989
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Methylphenidate combined with aripiprazole in children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder: a randomized crossover trial.
    Zeni CP; Tramontina S; Ketzer CR; Pheula GF; Rohde LA
    J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):553-61. PubMed ID: 19877980
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risperidone reduces aggression in boys with a disruptive behaviour disorder and below average intelligence quotient: analysis of two placebo-controlled randomized trials.
    LeBlanc JC; Binder CE; Armenteros JL; Aman MG; Wang JS; Hew H; Kusumakar V
    Int Clin Psychopharmacol; 2005 Sep; 20(5):275-83. PubMed ID: 16096518
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Functional outcomes from a head-to-head, randomized, double-blind trial of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder and an inadequate response to methylphenidate.
    Nagy P; Häge A; Coghill DR; Caballero B; Adeyi B; Anderson CS; Sikirica V; Cardo E
    Eur Child Adolesc Psychiatry; 2016 Feb; 25(2):141-9. PubMed ID: 25999292
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder.
    Greenhill LL; Muniz R; Ball RR; Levine A; Pestreich L; Jiang H
    J Am Acad Child Adolesc Psychiatry; 2006 Jul; 45(7):817-23. PubMed ID: 16832318
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized controlled double-blind trial of optimal dose methylphenidate in children and adolescents with severe attention deficit hyperactivity disorder and intellectual disability.
    Simonoff E; Taylor E; Baird G; Bernard S; Chadwick O; Liang H; Whitwell S; Riemer K; Sharma K; Sharma SP; Wood N; Kelly J; Golaszewski A; Kennedy J; Rodney L; West N; Walwyn R; Jichi F
    J Child Psychol Psychiatry; 2013 May; 54(5):527-35. PubMed ID: 22676856
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and Safety of SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled, Forced-Dose Clinical Study.
    Weisler RH; Greenbaum M; Arnold V; Yu M; Yan B; Jaffee M; Robertson B
    CNS Drugs; 2017 Aug; 31(8):685-697. PubMed ID: 28712074
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A naturalistic study of predictors and risks of atypical antipsychotic use in an attention-deficit/hyperactivity disorder clinic.
    Weiss M; Panagiotopoulos C; Giles L; Gibbins C; Kuzeljevic B; Davidson J; Harrison R
    J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):575-82. PubMed ID: 19877982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.